Nephrocare Health IPO valued at ₹871.05 crore, comprises a fresh issue of 0.77 crore shares worth ₹353.40 crore and an offer for sale of 1.13 crore shares totaling ₹517.64 crore.
The subscription window is open from December 10 to December 12, 2025, with allotment expected on December 15. The stock is set to list on BSE and NSE on December 17, 2025. The IPO price band is ₹438–₹460 per share, and the retail minimum investment stands at ₹14,720 for a lot of 32 shares.
Nephrocare Health IPO recorded a subscription of 0.46 times overall as of 10:29:33 AM on December 12, 2025 (Day 3). The issue was subscribed 0.60 times in the retail segment, 0.29 times by QIBs (excluding anchor), and 0.34 times in the NII category.
Nephrocare Health has launched a book-built IPO worth ₹871.05 crore, including a fresh issue of 0.77 crore shares (₹353.40 crore) and an OFS of 1.13 crore shares (₹517.64 crore).
The issue is open for bidding from December 10–12, 2025, with allotment scheduled for December 15 and listing on BSE and NSE on December 17. Priced between ₹438 and ₹460 per share, the IPO requires a minimum retail investment of ₹14,720 for one lot of 32 shares.
As of 10:29:33 AM on Day 3 (December 12, 2025), the Nephrocare Health IPO reached 0.46x overall subscription, including 0.60x in retail, 0.29x in QIB (ex-anchor), and 0.34x in the NII segment.
The table below breaks down the Nephrocare Health share allocation for different categories, highlighting the number of shares and their percentage of the total issue. However, the key focus remains on the quotas allocated to retail investors and HNIs, as they are the most relevant for individual investors.
| Investor Category | Shares Offered |
| QIB Shares Offered | 94,26,143 (49.78%) |
| – Anchor Investor Shares | 56,57,919 (29.88%) |
| – QIB (Ex-Anchor) Shares | 37,68,224 (19.90%) |
| NII (HNI) Shares Offered | 28,27,843 (14.93%) |
| – bNII (> ₹10L) | 18,85,229 (9.96%) |
| – sNII (< ₹10L) | 9,42,614 (4.98%) |
| Retail Shares Offered | 65,98,301 (34.85%) |
| Employee Shares Offered | 83,532 (0.44%) |
| Total Shares Offered | 1,89,35,819 (100.00%) |
| Category | Subscription (times) |
| Qualified Institutional Buyers | 0.29 |
| Non-Institutional Investors | 0.34 |
| Retail Individual Investors | 0.60 |
| Total shares | 0.46 |
Note: The subscription details are as of Dec 12, 2025
Nephrocare Health Services Ltd delivers comprehensive dialysis care through an extensive network of clinics across India and select global markets. Its offerings span diagnosis, haemodialysis, home and mobile dialysis, wellness programs, and an in-house pharmacy.
As of September 30, 2025, the company operated 519 clinics, including 51 in the Philippines, Uzbekistan, and Nepal, and runs the world’s largest dialysis clinic in Uzbekistan. In India, Nephrocare is present in 288 cities across 21 states and 4 union territories, with 77.53% of its centers located in tier II and tier III regions to address critical healthcare gaps.
In FY25, Nephrocare served 29,281 patients and performed 2,885,450 dialysis sessions—representing nearly 10% of India’s dialysis patient population. By September 30, 2025 alone, it had treated 31,046 patients and conducted 1,591,377 sessions in India. The company also operates 5,562 dialysis machines.
Nephrocare collaborates with leading hospital chains such as Max Super Speciality Hospital, Fortis Escorts, Care Hospitals, Wockhardt, Paras Healthcare, CMRI, Jehangir Hospital, and Ruby Hall Clinic to manage in-house dialysis centers.
Know more about IPO allotment status and check your application details online for the latest updates on share allocation.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Dec 12, 2025, 11:25 AM IST
Nikitha Devi
Nikitha is a content creator with 7+ years of experience in the financial domain. Specialising in personal finance, investments, and market insights, Nikitha simplifies complex financial topics, making them accessible to readers.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
